Overview

An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Status:
Terminated
Trial end date:
2021-06-09
Target enrollment:
Participant gender:
Summary
This study will be conducted to evaluate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in participants with Rett syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
GW Research Ltd
Treatments:
Cannabidiol
Epidiolex
Pharmaceutical Solutions